We have in one of our portfolios. We do not recommend Idea because of many other reasons, but Bharti is definitely there. For telecom as such have a positive view. Reliance is also one of our top picks in various portfolios, says Daljeet Singh Kohli, CIO, Stockaxis.com.
Do you think the telecom sector has turned around after a long time?
The government has taken a lot of positive measures in the past few months, and they are all being executed one by one now.
Do you think the telecom sector has turned around after a long time?
The government has taken a lot of positive measures in the past few months, and they are all being executed one by one now.
The telecom department is releasing bank guarantees of Rs 20,000 crore, and it’s again very positive for both these companies. We have Bharti Airtel in one of our portfolios. We do not recommend Idea because of many other reasons, but Bharti is definitely there. For telecom as such have a positive view. Reliance is also one of our top picks in various portfolios. So that is not just because of telecom, but telecom is a major part of Reliance. These stocks are not a part of my personal or my family’s portfolio. But all of these are recommended to our clients and are part of some or the other portfolios.
In terms of pharma names, what is the one that you like? Do you think the two-quarters pressure in terms of pricing was only Covid-related?
Pharma will remain an underperformer as a broad package. Within that, some companies that can perform, especially companies with exposure to the US market, are seeing a lot of pricing pressure.
Many companies mentioned that for certain products, the selling price is lesser than their cost of production. So that is a dire state of pricing generic in the US. The companies that will do well in India will be probably the ones with domestic formulation and a well-established distribution system. In healthcare, maybe hospitals will do well. We are positive about Apollo Hospitals, Max Healthcare, Fortis. All three of them are of interest to us.
The only pharma stock which is right now in the portfolio is Gland Pharma because of its differentiated product portfolio in injectables. These injectables are used in operation theatres. So critical requirement and their next leg of growth will come from biosimilars. Fosun Pharma, their parent company in China, could be a big help for them. Otherwise, we have a little cautious view on the overall sector.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
